An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study. Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years. The personalized cell therapy reprograms a patient’s immune system and offers the potential of long-term success.
“As we continue to follow children in this study, we see exciting results for patients who have exhausted their other treatment options,” said study leader Stephan A. Grupp, M.D., Ph.D., a pediatric oncologist at The Children’s Hospital of Philadelphia and a Professor of Pediatrics at the Perelman School of Medicine of the University of Pennsylvania. Grupp described outcomes and follow-up results of this pilot clinical trial for pediatric patients with ALL in a press…
View original 557 more words
Filed under: cancer alternative medicine
via WordPress http://ift.tt/1yPbjNA
No comments:
Post a Comment